← Human Trials & Peer-Reviewed Studies
Delay of cone degeneration in retinitis pigmentosa using a 12-month treatment with Lycium barbarum supplement.
Plain-language guide to PMID 30877066 (2019): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 30877066
- Journal
- Journal of ethnopharmacology
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Chan HH et al. (9 authors)
- DOI
- 10.1016/j.jep.2019.03.023
- Registered trial
- NCT02244996
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
Cone rescue is a potential method for delaying deterioration of visual function in Retinitis pigmentosa (RP).
This study aimed to investigate the treatment effect of Lycium barbarum L.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
The investigation was a double-masked and placebo-controlled clinical study.
The secondary outcomes were sensitivity changes of the central visual field, amplitude of full-field electroretinogram (ffERG) (including scotopic maximal response and photopic cone response), and average macular thickness.
What Was Measured
PubMed files the paper under topics including Dietary Supplements, Drugs, Chinese Herbal, Electroretinography, Lycium, Medicine, Chinese Traditional, Neuroprotective Agents and Retinal Cone Photoreceptor Cells.
The authors tagged it with the keywords Antioxidant (2.084), Clinical trial (2.172), Lycium barbarum, Neuroprotection, Retinal degeneration and Retinitis pigmentosa.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (Journal of ethnopharmacology), a journal based in Ireland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.